Coming Soon – May 2019 Pediatric asthma pharmacotherapy has two main goals...
Coming Soon – May 2019 Pediatric asthma pharmacotherapy has two main goals: address underlying airway inflammation and promote bronchodilation. Physicians use two...
Coming Soon – March 2019 Pharmacotherapy for adult asthma has two main...
Coming Soon – March 2019 Pharmacotherapy for adult asthma has two main goals: address underlying airway inflammation and promote bronchodilation. Two types of therapy a...
Dupixent (Sanofi/Regeneron), a first-in-class biologic that inhibits IL-4/IL-...
Dupixent (Sanofi/Regeneron), a first-in-class biologic that inhibits IL-4/IL-13 signaling, was approved for the treatment of eosi......
The asthma market consists of many well-established therapies, including...
The asthma market consists of many well-established therapies, including inhaled agents (e.g., GlaxoSmithKline’s Advair/Seretide, AstraZeneca’s Symbicort, Boehringer Ingelheim...
Market Outlook The asthma market in the EU5 is highly competitive. A large...
Market Outlook The asthma market in the EU5 is highly competitive. A large number of approved agents are available inc......
DRG Epidemiology's coverage of asthma comprises epidemiological estimates...
DRG Epidemiology's coverage of asthma comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report the prevalence of asthma for each country as well......
DRG Epidemiology’s coverage of asthma comprises epidemiological estimates of...
DRG Epidemiology’s coverage of asthma comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the prevalence of asthma for each country, as well...
DRG Epidemiology’s coverage of asthma comprises epidemiological estimates of...
DRG Epidemiology’s coverage of asthma comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the prevalence of asthma for each country, as...
DRG Epidemiology’s coverage of asthma comprises epidemiological estimates of...
DRG Epidemiology’s coverage of asthma comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the prevalence of asthma for each country, as...
DRG Epidemiology’s coverage of asthma comprises epidemiological estimates of...
DRG Epidemiology’s coverage of asthma comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the prevalence of asthma for each country, as...
DRG Epidemiology’s coverage of asthma comprises epidemiological estimates of...
DRG Epidemiology’s coverage of asthma comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the prevalence of asthma for each country, as...
MARKET OUTLOOK Despite the availability of multiple anti-inflammatory agents...
MARKET OUTLOOK Despite the availability of multiple anti-inflammatory agents and bronchodilators, considerable unmet need remains for patients with severe asthma. Typica......
The U.S. asthma market has become increasingly crowded with a large number of...
The U.S. asthma market has become increasingly crowded with a large number of approved therapies. Those include several LABA/...
MARKET OUTLOOK Asthma pharmacotherapy has two main goals: to address...
MARKET OUTLOOK Asthma pharmacotherapy has two main goals: to address underlying airway inflammation and promote bronchodilation. Physicians use two types of therapy to achieve these goal......
Market Outlook The dynamics within the LABA/ICS FDC, LAMA, and biological...
Market Outlook The dynamics within the LABA/ICS FDC, LAMA, and biological drug classes will continue to shape the......
Although several effective anti-inflammatory agents and bronchodilators are...
Although several effective anti-inflammatory agents and bronchodilators are available to control disease in mild-to-moderate asthmatics, great unmet need exists in the treatment of severe disease.......
Abstract: Owing to the large diagnosed prevalent population, relatively high...
Abstract: Owing to the large diagnosed prevalent population, relatively high rates of drug treatment across patients of all disease severities, and high rates of polypharma......
Device choice has long been a driver of sales of certain inhaled therapies,...
Device choice has long been a driver of sales of certain inhaled therapies, especially those available in multiple inhalers. With generic LAMA...
Emerging Therapies: Nucala (US) is a three-wave, syndicated, detailed,...
Emerging Therapies: Nucala (US) is a three-wave, syndicated, detailed, expanded analysis that tracks the introduction of Nucala, the first IL-5 inhibitor approved to treat eosinophilic asthma. Th......
Owing to the large diagnosed prevalent population, high rates of drug treatment...
Owing to the large diagnosed prevalent population, high rates of drug treatment across patients of all disease severities, and high rates of polypharmacy—particularly among the moderate/severe popu......
